Clinical trials
Phase 1/2 Squamous Cell Carcinoma of Head and Neck trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
27 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 4 |
| 2023 | 5 |
| 2024 | 4 |
| 2025 | 6 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 10 |
| Unknown status | 6 |
| Active, not recruiting | 5 |
| Completed | 4 |
| Enrolling by invitation | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| West China Hospital | 3 |
| DualityBio Inc. | 2 |
| Fudan University | 2 |
| Jacobio Pharmaceuticals Co., Ltd. | 2 |
| Akeso | 1 |
| Amgen | 1 |
| Beijing Biotech | 1 |
| Beijing Immunochina Medical Science & Technology Co., Ltd. | 1 |
| CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 1 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Squamous Cell Carcinoma of Head and Neck | 27 |
| Carcinoma, Non-Small-Cell Lung | 10 |
| Breast Neoplasms | 4 |
| Esophageal Neoplasms | 4 |
| Head and Neck Neoplasms | 4 |
| Uterine Cervical Neoplasms | 4 |
| Esophageal Squamous Cell Carcinoma | 3 |
| Small Cell Lung Carcinoma | 3 |
| Carcinoma, Transitional Cell | 2 |
| Endometrial Neoplasms | 2 |
Trials
Showing 1 to 25 of 27. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.